M. N. Potter, MB; M. G. Mott, MB; A. Oakhill, MB
To the Editor: Granulocyte-macrophage colony-stimulating factor (GM-CSF) is currently being studied as a possible therapy for severe aplastic anemia, although the myelopoietic response to such therapy is usually only transient (1) and is often disappointing in patients with very severe neutropenia (2). Adverse metabolic effects associated with this treatment are rare, but hypokalemia in the setting of GM-CSF therapy has recently been described (3). We report a case of acute hypocalcemia and hypomagnesemia causing tetany in a patient with severe aplastic anemia who was treated with human recombinant mammalian glycosylate (rh) GM-CSF (Sandoz-Schering Plouth, Basel, Switzerland).
A 4-year-old boy with
Learn more about subscription options.
Register Now for a free account.
Potter MN, Mott MG, Oakhill A. Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), Hypocalcemia, and Hypomagnesemia. Ann Intern Med. 1990;112:715. doi: 10.7326/0003-4819-112-9-715_1
Download citation file:
Published: Ann Intern Med. 1990;112(9):715.
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only